Evidence-Based Medicine Guidelines
Topical pimecrolimus for eczema
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Topical Pimecrolimus for Eczema." Evidence-Based Medicine Guidelines, John Wiley & Sons, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/455494/all/Topical_pimecrolimus_for_eczema.
Topical pimecrolimus for eczema. Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. https://evidence.unboundmedicine.com/evidence/view/EBMG/455494/all/Topical_pimecrolimus_for_eczema. Accessed March 27, 2025.
Topical pimecrolimus for eczema. (2025). In Evidence-Based Medicine Guidelines. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/EBMG/455494/all/Topical_pimecrolimus_for_eczema
Topical Pimecrolimus for Eczema [Internet]. In: Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. [cited 2025 March 27]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/455494/all/Topical_pimecrolimus_for_eczema.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Topical pimecrolimus for eczema
ID - 455494
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/455494/all/Topical_pimecrolimus_for_eczema
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
